Uchida, Takahito
Sugiura, Yuki
Sugiyama, Eiji
Maeda, Rae
Tanaka, Kenji F.
Suematsu, Makoto
Mimura, Masaru
Uchida, Hiroyuki
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP22H02833)
Japan Agency for Medical Research and Development,Japan (JP19gm1210009)
Japan Agency for Medical Research and Development (JP20zf0127003, 19dm0307102h0001)
Article History
Received: 20 March 2023
Accepted: 11 August 2023
First Online: 14 August 2023
Competing interests
: T.U. has received grants from the SENSHIN Medical Research Foundation (Osaka, Japan) within the past two years. M.M. has received speaker honoraria from Biogen Japan, Bayer Pharmaceuticals, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Demant Japan, Eisai, Eli Lilly, Fuji Film RI Pharma, Hisamitsu Pharmaceutical, H.U. Frontier, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Mylan EPD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Teijin Pharma, and Viatris in the past two years. He has also received grants from Daiichi Sankyo, Eisai, Fronteo, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura within the past two years outside of the submitted work. H.U. has received grants from Daiichi Sankyo, Eisai, Mochida, Otsuka, and Sumitomo Pharma; speaker fees from Eisai, Janssen, Lundbeck, Meiji Seika Pharma, Otsuka, and Sumitomo Pharma; and advisory board fees from Lundbeck, Sumitomo Pharma, Takeda Pharmaceutical Company, and Boehringer Ingelheim Japan. Y.S., E.S., R.M., K.T., and M.S. have no competing interests.